GlobeNewswire

Nexstim Plc: Change in the composition of the Shareholders’ Nomination Committee

Share

Company announcement, inside information, Helsinki, 14 September 2020 at 14.30 (EEST)

Nexstim Plc: Change in the composition of the Shareholders’ Nomination Committee

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) is announcing a change in the composition of the Shareholders’ Nomination Committee.

Kyösti Kakkonen representing Joensuun Kauppa ja Kone Oy has been appointed as a new member of the Nomination Committee. He is replacing Katya Smirnyagina, representative of Capricorn Health Tech Fund in the Nomination Committee.

Leena Niemistö, Chairperson of the Board of Nexstim and representative of its largest shareholder, continues to chair the Nomination Committee, and Ossi Haapaniemi continues as a member of the Committee.

According to the document establishing Nexstim’s Nomination Committee, it must have three to four members. The three largest shareholders of the Company each nominate one member; if a shareholder does not exercise the right to nominate a representative, the right is passed on to the next largest shareholder.

The new Nomination Committee will start its work during September.


Further information is available on the website www.nexstim.com or by contacting:

Leena Niemistö, Chairperson of the Board
+358 9 2727 170
leena.niemisto@nexstim.com

Erik Penser Bank AB (Certified Adviser)                              
 +46 8 463 83 00
certifiedadviser@penser.se

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a pioneering non-invasive brain stimulation technology entitled SmartFocus®. SmartFocus® is based on transcranial magnetic stimulation (TMS) combined with a 3D navigation system. The unique technology allows the required area of the brain to be stimulated accurately and individually.

The SmartFocus® TMS technology is used in NBT® (Navigated Brain Therapy) equipment developed by Nexstim. Marketing and distribution of the equipment for the treatment of serious depression in the USA has been authorised by FDA. NBT® equipment has been CE approved in Europe for the treatment of serious depression and chronic neuropathic pain.

Furthermore, Nexstim is marketing the Navigated Brain Stimulation (NBS) equipment, developed by it and based on   SmartFocus® TMS technology. Nexstim’s NBS system is the only FDA cleared and CE marked navigating TMS equipment for the pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden trading facilities.

For more information, please visit www.nexstim.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Leasinvest Real Estate SCA: Important lease in the building Mercator in Luxembourg30.9.2020 17:40:00 CESTPress release

New lease for a floor in the building Mercator Leasinvest Real Estate has just concluded a new lease for 1,560 m² with CHL – ‘Centre Hospitalier de Luxembourg’, in the building Mercator located Route d'Arlon 110-112 in the Grand Duchy of Luxembourg. This new lease concretises the in-principle agreement already announced in the half-year financial report published on 19 August 2020. The rent price amounts to € 22/m²/month and the contract starts tomorrow, 1 October 2020. The building Mercator has a total surface area of 8,641 m² of offices, spread across 5 floors and comprises 104 parking spaces, and benefits from an exceptional location in the capital of the Grand Duchy along the Route d’Arlon, one of the main axes to the City of Luxembourg. Moreover, the building Mercator is located nearby Luxembourg’s main hospital, around which an important number of (para)medical businesses are located. This transaction was realised with the intervention of Cushman & Wakefield. Michel Van Geyte, CE

Ress Life Investments A/S: Ress Life Investments A/S publishes Net Asset Value (NAV)30.9.2020 17:05:00 CESTPress release

Ress Life Investments Holbergsgade 14, 2 tv DK-1057 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 30 September 2020 Corporate Announcement 36/2020 Ress Life Investments A/S publishes Net Asset Value (NAV). Ress Life Investments A/S publishes the Net Asset Value (NAV) per share and performance data as of 15 September 2020. NAV per share in USD: 2064.01 NAV per share in EUR: 1735.63 The performance during the first half of September was -0.49% in USD. The year-to-date net performance is 5.37% in USD. Assets under management (AUM) was 215.0 million US dollars. Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB. Contact person: Gustaf Hagerud gustaf.hagerud@resscapital.com Tel + 46 8 545 282 27 Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Investment Information Docume

Vaisala’s financial information and Annual General Meeting in 202130.9.2020 17:00:00 CESTPress release

Vaisala Corporation Stock exchange release September 30, 2020 at 6:00 p.m. EEST Vaisala’s financial information and Annual General Meeting in 2021 Vaisala Corporation will publish its Financial Statement Release, Half Year Financial Report and two Interim Reports during 2021 as follows: - February 19, 2021: Financial Statement Release 2020 - April 29, 2021: Interim Report January–March 2021 - July 23, 2021: Half Year Financial Report 2021 - October 28, 2021: Interim Report January–September 2021 The Annual Report 2020 will be published at vaisala.com by the end of week 9. Vaisala Corporation’s Annual General Meeting is scheduled for Tuesday, March 30, 2021. The Board of Directors of the company will convene the meeting. More information Paula Liimatta, Business Controller and Head of Investor Relations Tel. +358 40 580 3521 Distribution Nasdaq Helsinki Key media vaisala.com Vaisala is a global leader in environmental and industrial measurement. Building on over 80 years of experience,

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING30.9.2020 16:20:00 CESTPress release

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-10-02 Transaction type:SEK CreditTender date:2020-10-02Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-10-06Final repayment date2024-10-07Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON OCTOBER 2 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: eol@riksbank.se Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se

Change in numbers of shares and votes in Saniona AB (publ)30.9.2020 16:00:00 CESTPress release

PRESS RELEASE September 30, 2020 During September, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the exercising of warrants of series TO 2. As of September 30, 2020, the registered number of shares and votes in Saniona amounts to 62,372,831. For more information, please contact Trista Morrison, Chief Communications Officer. Mobile + 1 (858) 229 1738. Email: trista.morrison@saniona.com This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 4 p.m. CET on September 30, 2020. About Saniona Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments f